Preview

Медицинский Совет

Расширенный поиск

Гиперфосфатемия при хронической болезни почек

https://doi.org/10.21518/2079-701X-2019-16-78-85

Полный текст:

Аннотация

Гиперфосфатемия при почечной патологии является ключевым фактором развития минеральных и костных нарушений. Она может развиться уже при начальном снижении фильтрационной функции почек и быть предиктором формирования сосудистой кальцификации и повышения риска развития сердечно-сосудистых осложнений у пациентов с хронической болезнью почек, особенно находящихся на лечении программным гемодиализом. Применение кальций-несодержащих фосфорсвязывающих препаратов без риска развития гиперкальциемии позволяет замедлить развитие кальцификации сосудов, сократить частоту неблагоприятных кардиоваскулярных событий и снизить смертность у пациентов с хронической болезнью почек.

Об авторах

С. А. Мартынов
Национальный медицинский исследовательский центр эндокринологии
Россия
Мартынов Сергей Андреевич, д.м.н., заведующий кабинетом экс - тракорпоральных методов лечения почечной патологии


М. Ш. Шамхалова
Национальный медицинский исследовательский центр эндокринологии
Россия
Шамхалова Минара Шамхаловна, д.м.н., заведующая отделением диабетической болезни почек и посттрансплантационной реаби - литации


Список литературы

1. Ospina C.A.G., Holguin M.C., Escobar D.C., Valencia C.A.R.Importance of hyperposphatemia in chronic kidney disease, how to avoid it and treat it by nutritional measures. Rev Colomb Nefrol. 2017;4(1):24-41. doi: 10.22265/acnef.4.1.270.

2. Hruska K.A., Mathew S., Lund R., Qiu P., Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148-157. doi: 10.1038/ ki.2008.130.

3. Prasad N., Bhadauiria. Renal phosphate handling: phisiology. Indian Endocrinol Metab. 2013;17(4):620-227. doi: 10.4103/2230- 8210.113752.

4. Takashi Y., Fukumoto S. FGF23-Klotho axis in CKD. Renal Replacement Therapy. 2016;(2):20. doi 10.1186/s41100-016-0032-4.

5. Kumar R., Thopsmon R. The regulation of parathyroid hormone secretion. J Amer Soc Nephrol. 2011;22(2):224-224. doi: 10.1681/ ASN.2010020186.

6. Cannata-Andía J.B., Martin K.J. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2016;31(4):541- 547. doi: 10.1093/ndt/gfv055.

7. Hutchison A.J., Smith C.P., Brenchley P.E.C. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7(10):578- 589. doi: 10.1038/nrneph.2011.112.

8. Jüppner H. Phosphate and FGF-23. Kidney Int Suppl. 2011;(121):24-27. doi: 10.1038/ ki.2011.27.

9. Sigrist M., Bungay P., Taal M.W., McIntyre C.W. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant. 2006;21(3):707-714. doi: 10.1093/ ndt/gfi236.

10. Бирагова М.С., Мартынов С.А., Грачева С.А. Нарушение фосфорно-кальциевого обмена у пациентов с сахарным диабетом и хронической болезнью почек. Сахарный диабет. 2012;(4):74-80. doi: 10.14341/2072-0351-5542. Biragova M.S., Gracheva S.A., Martynov S.A. Compromised calcium and phosphorus metabolism in patients with diabetes mellitus and chronic kidney disease. Sakharnyy diabet = Diabetes mellitus. 2012;(4):74-80. (In Russ.) doi: 10.14341/2072-0351-5542.

11. Li X., Wang H.Y., Giachelli C.M. Role of sodiumdepended phosphate co-transporter, Pit-1, in vascular smooth muscle cell calcification. Circulation Research. 2006;(98):905–912. doi: 10.1161/01.RES.0000216409.20863.e7.

12. Cannata-Andia J.B., Roman-Garcia P., Hruska P. The connection between vascular calcification and bone health. Nephrol Dial Transplant. 2011;26(11):3429-3436. doi: 10.1093/ndt/ gfr591.

13. Dhingra D., Gona P., Benjamin E.J., Wang T.J., Aragam J., D’Agostino Sr., Kannel W.B., Vasan R.S. Relation of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in community. Eur J Heart Fail. 2010;12(8):812-818. doi: 10.1093/ eurjhf/hfq106.

14. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31(4):607-617. doi: 10.1053/ajkd.1998.v31.pm9531176.

15. Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Cholesterol And Recurrent Events Trial Investigators.Relationship between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627-2633. doi: 10.1161/ CIRCULATIONAHA.105.553198.

16. Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20(2):397-404. doi: 10.1681/ASN.2008020141.

17. Kathryn L. Adeney, David S. Siscovick, Joachim H. Ix, Stephen L. Seliger, Michael G. Shlipak, Nancy S. Jenny, Bryan R. Kestenbaum. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20(2):381–387. doi: 10.1681/ASN.2008040349.

18. Chue C.D., Edwards N.C., Moody W.E., Steeds R.P., Townend J.N., Ferro C.J. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: A cardiac magnetic resonance study. Heart. 2012;98(3):219-224. doi: 10.1136/ heartjnl-2011-300570.

19. Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphate and left ventricular hypertrophy in young adults: The coronary artery risk development in young adults study. Kidney Blood Press Res. 2009;32(1):37-44. doi: 10.1159/000203348.

20. Kestenbaum B., Sampson J.N., Rudser K.D., Patterson D.J., Seliger S.L., Young B., Sherrard D.J., Andress D.L. Serum phosphate level and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520- 528. doi: 10.1681/ASN.2004070602.

21. Palmer S.C., Hayen A., Macaskill P., Pellegrini F., Craig J.C., Elder G.J., Strippoli G.F. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119-27. doi: 10.1001/ jama.2011.308.

22. Cannata-Andia J.B., Martin K.J. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2016;31(4):541-7. doi: 10.1093/ndt/gfv055.

23. Beto J.A., Ramirez W.E., Bansal V.K. Medical nutrition therapy in adults with chronic kidney disease: integrating evidence and consensus into practice for the generalist registered rietitian Nutritionist. J Acad Nutr Diet. 2014;114(7):1077-87. doi: 10.1016/j.jand. 2013.12.009.

24. Moe S.M., Zidehsarai M.P., Chambers M.A., Jackman L.A., Radcliffe J.S., Trevino L.L., Donahue S.E., Asplin J.R. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):257-264. doi: 10.2215/CJN.05040610.

25. Chauveau P., Koppe L., Combe C., Lasseur C., Trolonge S., Aparicio M. Vegeterian diets and chronic kidney disease. Nephrol Dial Transplant. 2019;34(2):199-207. doi: 10.1093/ndt/gfy164.

26. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi: 10.1016/j. kisu.2017.04.001.

27. Cannata-Andía J.B., Fernández-Martín J.L., Locatelli F., London G., Gorriz J.L., Floege J., Ketteler M., Ferreira A., Covic A., Rutkowski B., Memmos D., Bos W.J., Teplan V., Nagy J., Tielemans C., Verbeelen D., Goldsmith D., Kramar R., Martin P.Y., Wüthrich R.P., Pavlovic D., Benedik M., Sánchez J.E., Martínez-Camblor P., Naves-Díaz M., Carrero J.J., Zoccali C. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84(5):998-1008. doi: 10.1038/ki.2013.185.

28. Merjanian R., Budoff M., Adler S., Berman N., Mehrotra R. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int. 2003;64(1):263-271. doi: 10.1046/j.1523-1755.2003.00068.x.

29. Chan S., Au K., Francis R., Made D.W., Johnson D.W., Pillars P. Phosphate binders in patients with chronic kidney disease Aust Prescr. 2017;40(1):10–14. doi: 10.18773/austprescr.2017.002.

30. Vervloet M.G., van Ballegooijen J. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93(5):1060- 1072. doi: 10.1016/j.kint.2017.11.036.

31. Мартынов С.А., Бирагова М.С., Шамхалова М.Ш., Шестакова М.В. Гиперфосфатемия при хронической болезни почек. Медицинский совет. 2013;(5-6):98-101. Режим доступа: https://elibrary.ru/item.asp?id=21168655. Martynov S.A., Biragova M.S., Shamkhalova M. Sh., Shestakova M.V. Hyperphosphatemia of chronic kidney disease. Meditsinskiy sovet = Medical Council. 2013;(5-6):98-101. (In Russ.) Available at: https://elibrary.ru/item. asp?id=21168655.

32. Wills M.R., Savory J. Aluminium poisoning dialysis encephalopathy, osteomalacia, and anemia. Lancet. 1983;2(8340):29-34. doi: 10.1016/ s0140-6736(83)90014-4.

33. Elder G.J., Center J. The role of calcium and non-calcium-based phosphate binders in cronic kidney disease. Nephrology (Carlton). 2017;22(Suppl 2):42-46. doi: 10.1111/ nep.13031.

34. Burke S., Amin N., Incerti C., Plone M., Watson N. Sevelamer hydrochloride, a nonabsorbed phospaht-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol. 2001;41(2):193-198. doi: 10.1177/00912700122009872.

35. Burke S., Amin N., Incerti C., Plone M., Lee J.W. Sevelamer hydrochloride, a phospaht-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensive in healthy volunteers. J Clin Pharmacol. 2001;(41):199-205. Available at: http://www. biomedsearch.com/nih/Sevelamerhydrochloride-Renagel-phosphate-binding/11210402.html.

36. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-252. doi: 10.1046/j.1523-1755.2002.00434.x.

37. Othmane T.E.H., Bakonyi G., Egresits J. et al. Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: A prospective observational study. Hemodial Int. 2007;11(Suppl 3):13-21. doi: 10.1111/j.1542-4758.2007.00224.x.

38. Takenaka T., Suzuki H. New strategy to attenuate pulse wave velocity in haemodialysis patients. Nephrol Dial Transplant. 2005;20:811– 816. doi: 10.1093/ndt/gfh656.

39. Suki W.N., Zabaneh R., Cangiano J.L., Reed J., Fischer D., Garrett L., Ling B.N., Chasan-Taber S., Dillon M.A., Blair A.T., Burke S.K. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130-7. doi: 10.1038/sj. ki.5002466.

40. Block G.A., Raggi P., Bellasi A., Kooienga L., Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438-441. doi: 10.1038/sj.ki.5002059.

41. Di Iorio B., Molony D., Bell C., Cucciniello E., Bellizzi V., Russo D., Bellasi A; INDEPENDENT Study Investigators. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771- 778. doi: 10.1053/j.ajkd.2013.03.023.

42. Jamal S., Vandermeer B., Raggi P., Mendelssohn D.C., Chatterley T., Dorgan M., Lok C.E., Fitchett D. Effect of calcium-based versus non-calcium based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268-77. doi: 10.1016/S0140- 6736(13)60897-1.

43. Patel L., Bernard L.M., Elder G. Sevelamer versus calcium based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trial. Clin J Am Soc Nephrol. 2016;11(2):232-44. doi: 10.2215/ CJN.06800615.

44. de Francisco A.L., Leidig M., Covic A.C., Ketteler M., Benedyk-Lorens E., Mircescu G.M., Scholz C., Ponce P., Passlick-Deetjen J. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25(11):3707-3717. doi: 10.1093/ndt/gfq292.

45. Covic A., Passlick-Deetjen J., Kroczak M., Büschges-Seraphin B., Ghenu A., Ponce P., Marzell B., de Francisco A.L. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant. 2013;28(9):2383-2392. doi: 10.1093/ndt/gft203.

46. Torregrosa J.V., González-Parra E., González M.T., Cannata-Andía J. Rufus study: efficacy and safety of lanthanum carbonate in clinical practice in Spain. Nefrologia. 2014;34(3):360- 368. doi: 10.3265/Nefrologia.pre2014. Mar.12287.

47. Shigematsu T., Tokumoto A., Nakaoka A., Arisaka H. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial. 2011;15(2):176- 84. doi: 10.1111/j.1744-9987.2010.00898.x.

48. Cernano V., Santoro D., Lacquaniti A., Constantino G., Visconti L., Buemi A., Buemi M. Phosphate binders for treatment of chronic kidney disease: role of iron oxyhydroxide. International Journal of Nephrology and Renovascular Disease. 2016;(9):11-19. doi: 10.2147/IJNRD.S78040.

49. Floege J., Covic A.C., Ketteler M., Rastogi A., Chong E.M., Gaillard S., Lisk L.J., Sprague S.M.; PA21 Study Group. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638-47. doi: 10.1038/ki.2014.58.


Для цитирования:


Мартынов С.А., Шамхалова М.Ш. Гиперфосфатемия при хронической болезни почек. Медицинский Совет. 2019;(16):78-85. https://doi.org/10.21518/2079-701X-2019-16-78-85

For citation:


Martynov S.A., Shamkhalova M.S. Hyperphosphatemia in chronic kidney disease. Meditsinskiy sovet = Medical Council. 2019;(16):78-85. (In Russ.) https://doi.org/10.21518/2079-701X-2019-16-78-85

Просмотров: 224


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)